135
Participants
Start Date
August 10, 2018
Primary Completion Date
June 30, 2019
Study Completion Date
August 31, 2025
Atezolizumab
Atezolizumab at a fixed dose of 1200 mg will be administered first by IV infusion Q3W on Day 1 of each 21-day cycle.
Tiragolumab
Tiragolumab at a fixed dose of 600 mg will be administered by IV infusion Q3W on Day 1 of each 21-day cycle.
Placebo
Placebo will be administered by IV infusion Q3W on Day 1 of each 21-day cycle.
Chang Gung Memorial Hospital - Linkou, Taoyuan District
Taipei Veterans General Hospital, Taipei
Hospital Univ Germans Trias i Pujol, Badalona
National Taiwan University Hospital, Taipei
Clinical Center of Serbia, Belgrade
Clinical Hospital Center Bezanijska Kosa, Belgrade
Hopital Nord AP-HM, Marseille
Seoul National University Bundang Hospital, Gyeonggi-do
Centre Georges François Leclerc, Dijon
Virginia Cancer Specialists, PC, Fairfax
Taipei Medical University ?Shuang Ho Hospital, New Taipei City
Clinica Universitaria Navarra (Madrid), Madrid
Hospital Universitario 12 de Octubre, Madrid
Hospital Universitario Puerta de Hierro - Majadahonda, Madrid
Chungbuk National University Hospital, Cheongju-si
Clinica Universitaria de Navarra, Pamplona
Institut Bergonié Centre Régional de Lutte Contre Le Cancer de Bordeaux Et Sud Ouest, Bordeaux
Florida Cancer Specialists - NORTH - SCRI - PPDS, St. Petersburg
SCRI Florida Cancer Specialists South, Fort Myers
Complejo Hospitalario Universitario Insular?Materno Infantil, Las Palmas de Gran Canaria
Centro Medico Quironsalud Sagrado Corazon, Seville
Hospital Universitario Virgen del Rocio, Seville
Institut De Cancerologie De L'Ouest, Saint-Herblain
Karmanos Cancer Institute, Detroit
ICO Paul Papin, Angers
Illinois Cancer Specialists, Arlington Heights
Illinois Cancer Care, Peoria
HCA Midwest Health, Kansas City
University of Kansas Medical Center, Westwood
National Cheng Kung University Hospital, North Dist.
Arizona Oncology Associates, PC - HAL, Tempe
Northwest Cancer Specialists - Vancouver, Vancouver
Kangbuk Samsung Hospital, Seoul
Severance Hospital, Yonsei University Health System, Seoul
Asan Medical Center, Seoul
Hospital General Universitario de Alicante, Alicante
Hospital Universitario Vall d'Hebron - PPDS, Barcelona
Lead Sponsor
Genentech, Inc.
INDUSTRY